All aboard Exact Sciences Ride of Broken Dreams.





































More likely to be bought out by one of the large diagnostic companies. Cologuard will face significant competition in the future but will still play a role. Other companies will have a more diversified portfolio to absorb the slowing or negative growth. The hope was liquid biopsy would be the next growth engine but reading what’s out there we will not be best in class. We should be ok employment wise for a while. Stock price who the heck knows. At some point you have to show a profit unless the growth was off the charts which does not seem to be the case. Fourteen years is a long time and growth is slowing.
 






More likely to be bought out by one of the large diagnostic companies. Cologuard will face significant competition in the future but will still play a role. Other companies will have a more diversified portfolio to absorb the slowing or negative growth. The hope was liquid biopsy would be the next growth engine but reading what’s out there we will not be best in class. We should be ok employment wise for a while. Stock price who the heck knows. At some point you have to show a profit unless the growth was off the charts which does not seem to be the case. Fourteen years is a long time and growth is slowing.
Why buy a test that hasn't been improved in 14 years?. The size of sample collected is obscene. Others can do the same test with 1/50th the sample volume. Drop a small sample in mail or at clinic instead of paying ups god knows how much to ship a massive bucket for each patient. Great job Kevin. 100 mil a quarter dropped on R&D and nothing to show since 2012.
 






Why buy a test that hasn't been improved in 14 years?. The size of sample collected is obscene. Others can do the same test with 1/50th the sample volume. Drop a small sample in mail or at clinic instead of paying ups god knows how much to ship a massive bucket for each patient. Great job Kevin. 100 mil a quarter dropped on R&D and nothing to show since 2012.
Um, this company has issues, but not as many as you think CG is the same as FIT test
 












I don't think you have any idea the problems ES is facing. Unreliable automation, lack of test growth or adoption, consecutive failed (delayed)launches and studies. Oblivious Exec leadership. The end is nigh.

Unfortunately the problems are costly. PO was supposed to save us and is a disaster. Extra launch failed miserably. MRD launch better knock it out of the ballpark, but it won’t.

What does PG do?
 










































so
We went from music of an old dead guy to trying to play off a show that ended seven years ago and another that’s total brain rot. Well done, marketing. What’s next? Elon Musk sponsorship? JFC
You have to realize that marketing hires people to judge the effectiveness of all the ads they spend money on.

And these people they pay come up with lots of fancy charts that says it is working.

I'm sure the data isn't biased to make it look like it's working :p